Insider Selling: Beigene, Ltd. (NASDAQ:ONC) COO Sells 51,921 Shares of Stock

Beigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu sold 51,921 shares of Beigene stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $261.59, for a total value of $13,582,014.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Xiaobin Wu also recently made the following trade(s):

• On Thursday, February 20th, Xiaobin Wu sold 21,267 shares of Beigene stock. The shares were sold at an average price of $240.07, for a total transaction of $5,105,568.69.
• On Tuesday, February 18th, Xiaobin Wu sold 30,654 shares of Beigene stock. The stock was sold at an average price of $240.74, for a total transaction of $7,379,643.96.

Beigene Stock Performance

NASDAQ:ONC opened at $247.07 on Monday. Beigene, Ltd. has a 1-year low of $126.97 and a 1-year high of $287.88. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. The stock has a market cap of $24.18 billion, a PE ratio of -29.98, a PEG ratio of 7.73 and a beta of 0.65.

Beigene (NASDAQ:ONC) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.55). The business had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. On average, research analysts forecast that Beigene, Ltd. will post -5.82 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on ONC shares. Bank of America raised shares of Beigene from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $207.00 to $320.00 in a research note on Monday, March 3rd. Macquarie raised their price objective on Beigene from $259.00 to $313.00 and gave the company an “outperform” rating in a report on Friday, February 28th.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.